AZD-7624 is primarily investigated for its potential therapeutic applications in the treatment of chronic obstructive pulmonary disease (COPD). It functions as a potent and selective inhibitor of phosphodiesterase 4 (PDE4), an enzyme that plays a key role in regulating inflammation and immune responses. By inhibiting PDE4, AZD-7624 helps reduce inflammation in the airways, which is a major contributor to the symptoms and progression of COPD. This makes it a promising candidate for improving lung function and reducing exacerbations in patients suffering from this chronic respiratory condition. Additionally, its selectivity for PDE4 may offer a better safety profile compared to non-selective PDE inhibitors, minimizing side effects such as nausea and gastrointestinal discomfort.